Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide

Journal of Clinical Oncology

Volumn 25, Issue 22, 2007, Pages 3344-3349

  Dimopoulos, Meletios Athanasios ^a   Anagnostopoulos, Athanasios ^b   Kyrtsonis, Marie Christine ^b   Zervas, Konstantinos ^b   Tsatalas, Constantinos ^b   Kokkinis, Garyfallia ^b   Repoussis, Panagiotis ^b   Symeonidis, Argyris ^b   Delimpasi, Souzana ^b   Katodritou, Eirini ^b   Vervessou, Elina ^b   Michali, Evridiki ^b   Pouli, Anastasia ^b   Gika, Dimitra ^b   Vassou, Amalia ^b   Terpos, Evangelos ^b   Anagnostopoulos, Nikolaos ^b   Economopoulos, Theophanis ^b   Pangalis, Gerasimos ^b  

^a ALEXANDRA HOSPITAL   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GANCICLOVIR; RITUXIMAB;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEMOGRAPHY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HERPES ZOSTER; HUMAN; HYPOALBUMINEMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 34548229503     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.10.9926     Document Type: Article

References (30)

1. Owen RG, Treon SP, Al-Katib A, et al: Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:110-115, 2003
2. Alexanian R, Weber D, Delasalle K, et al: Asymptomatic Waldenstrom's macroglobulinemia. Semin Oncol 30:206-210, 2003
3. Cesana C, Miqueleiz S, Bernuzzi P, et al: Smouldering Waldenstrom's macroglobulinemia: Factors predicting evolution to symptomatic disease. Semin Oncol 30:231-235, 2003
4. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al: Waldenstrom's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol 18:214-226, 2000
5. Gertz MA, Anagnostopoulos A, Anderson K, et al: Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:121-126, 2003
6. Kyle RA, Treon SP, Alexanian R, et al: Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:116-120, 2003
7. Weber D, Treon SP, Emmanouilides C, et al: Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:127-131, 2003
8. Dimopoulos MA, Zervas C, Zomas A, et al: Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 20:2327-2333, 2002
9. Kimby E, Treon SP, Anagnostopoulos A, et al: Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 6:380-383, 2006
10. Gertz MA, Rue M, Blood E, et al: Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 45:2047-2055, 2004
11. Treon SP, Emmanouilides C, Kimby E, et al: Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol 16:132-138, 2005
12. Rose AL, Smith BE, Maloney DG: Glucocorticoids and rituximab in vitro: Synergistic direct antiproliferative and apoptotic effects. Blood 100:1765-1773, 2002
13. Dimopoulos MA, Alexanian R: Waldenstrom's macroglobulinemia. Blood 83:1452-1459, 1994
14. García-Sanz R, Montoto S, Torrequebrada A, et al: Waldenstrom macroglobulinaemia: Presenting features and outcome in a series with 217 cases. Br J Haematol 115:575-582, 2001
15. Mohammad RM, Aboukameel A, Nabha S, et al: Rituximab, cyclophosphamide, dexamethasone (RCD) regimen induces cure in WSU-WM xenograft model and a partial remission in previously treated Waldenstrom's macroglobulinemia patient. J Drug Target 10:405-410, 2002
16. Weber DM, Dimopoulos MA, Delasalle K, et al: 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 30:243-247, 2003
17. Treon SP, Hunter Z, Barnagan AR: CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma 5:273-277, 2005
18. Hensel M, Villalobos M, Kornacker M, et al: Pentostatin/cyclophosphamide with or without rituximab: An effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma 6:131-135, 2005
19. Treon SP, Branagan A, Wasi P, et al: Combination therapy with rituximab and fludarabine in Waldenstrom's macroglobulinemia: ASH Annual Meeting Abstracts. Blood 104:753, 2004
20. Cabanillas F, Liboy J, Pavia O, et al: High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: A frequently unrecognized and easily treatable complication. Ann Oncol 17:1424-1427, 2006
21. Buske C, Dreyling MH, Eimermacher H, et al: Combined immuno-chemotherapy (R-CHOP) results in significantly superior response rates and time to treatment failure in first line treatment of patients with lymphoplasmacytoid/ic immunocytoma (LP-IC) - Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG): ASH Annual Meeting Abstracts. Blood 104:162, 2004
22. Ghobrial IM, Fonseca R, Greipp PR, et al: Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: An Eastern Cooperative Oncology Group Study. Cancer 101:2593-2598, 2004
23. Treon SP, Branagan AR, Hunter Z, et al: Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 15:1481-1483, 2004
24. Desikan R, Dhodapkar M, Siegel D, et al: High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia. Br J Haematol 105:993-996, 1999
25. Dreger P, Glass B, Kuse R, et al: Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenstrom's macroglobulinaemia. Br J Haematol 106:115-118, 1999
26. Anagnostopoulos A, Dimopoulos MA, Aleman A, et al: High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia. Bone Marrow Transplant 27:1027-1029, 2001
27. Anagnostopoulos A, Hari PN, Perez WS, et al: Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant 12:845-854, 2006
28. Morel P, Duhamel A, Gobbi P, et al: International Prognostic Scoring System (IPSS) for Waldenstrom's Macroglobulinemia (WM): ASH Annual Meeting Abstracts. Blood 108:127, 2006
29. Ghobrial IM, Fonseca R, Gertz MA, et al: Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 133:158-164, 2006
30. Treon SP, Gertz MA, Dimopoulos M, et al: Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia. Blood 107:3442-3446, 2006